Kidney Disease Clinical Trials in Los Angeles

Showing 261-280 of 308 trials

Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors

NCT01155258

RATIONALE: Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as vinorelbine ditartrate, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving temsirolimus together with vinorelbine ditartrate may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of giving temsirolimus and vinorelbine ditartrate together in treating patients with unresectable or metastatic solid tumors.

Extensive Stage Small Cell Lung CancerHereditary ParagangliomaMale Breast Cancer+45 more

University of Southern California19 participantsStarted Jun 2010

Los Angeles, California, United States

COMPLETED< 1 mile

Quantitative Imaging Metrics From CECT in Measuring Disease Response or Progression in Patients With Kidney Cancer

NCT02370290

This pilot research trial studies quantitative imaging metrics derived from contrast enhanced computed tomography (CECT) in enhancing assessment of disease status in patients with kidney cancer. Quantitative imaging is the extraction of quantifiable features from radiological images for the assessment of disease status. Collecting quantitative imaging metrics from CECT imaging may help doctors predict tumor aggressiveness and nuclear grade (tumor stage) and assess treatment response and prognosis in cancer imaging.

Renal Cell Carcinoma

University of Southern California74 participantsStarted Apr 2014

Los Angeles, California, United States

Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors

Quantitative Imaging Metrics From CECT in Measuring Disease Response or Progression in Patients With Kidney Cancer

Kidney Disease Trials in Other Cities

Delivery of Soluble Ferric Pyrophosphate (SFP) Via the Dialysate to Maintain Iron Balance in Hemodialysis Patients

Gadobutrol Enhanced MRA of the Renal Arteries

An Open-label, Prospective, Randomized, Multi-center, Phase II Comparative Trial of Thymoglobulin Versus Simulect for the Prevention of Delayed Graft Function and Acute Allograft Rejection in Renal Allograft Recipients.

Dialysis Clinical Outcomes Revisited (DCOR) Trial

Trial for Prevention of Contrast Nephropathy With Sodium Bicarbonate

Vorinostat in Treating Patients With Locally Recurrent or Metastatic Cancer of the Urothelium

Study to Evaluate the Prospective Payment System

Fasiglifam in Type 2 Diabetic Subjects With Chronic Kidney Disease Stage 4 or 5 on Hemodialysis

Anit-Inflammatory and Anti-Oxidative Nutrition in Dialysis Patients

Dietary Protein Requirements in Hemodialysis Patients

Study to Compare Sevelamer Carbonate Powder to Sevelamer Hydrochloride Tablets in Patients With CKD on Hemodialysis

Assessing the Pharmacokinetics of NKTR-118 in Subjects With Renal Impairment Compared to That in Subjects With Normal Renal Function

Study to Compare Conivaptan Pharmacokinetics in Subjects With Mild & Moderate Kidney Function Impairment to Subjects With Normal Kidney Function

Cross-Over Study of Sevelamer Hydrochloride and Sevelamer Carbonate

Multicenter, Prospective, Rand, PK Study of LCP-Tacro™ Compared to Prograf® Capsules in De Novo Adult Kidney Transplant

Pazopanib in Previously Treated Patients With Metastatic Renal Cell Carcinoma

A Study of Ramucirumab in Participants With Metastatic Renal Cell Carcinoma

The Effect of Rituximab on the Development of Anti-Donor Antibodies

Other Conditions in Los Angeles